Skip to content
Biodatica
Start free

BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB

UPTON, NY

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

2mo agoTrial registeredApr 21, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Momentum 79 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

818 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jan 1, 2026

    Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma · ACTIVE_NOT_RECRUITING · sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Efficacy and Survival Analysis of Perioperative Treatment of Locally Advanced Gastric or Gastroesophageal Junction Cancer

    ClinicalTrials.gov · NCT07429318 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Sep 18, 2025

    Colorectal Liver Metastases · RECRUITING · sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

    ClinicalTrials.gov · NCT06848842 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Apr 15, 2024

    Gastric Cancer · RECRUITING · sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

    ClinicalTrials.gov · NCT06417892 (opens the source filing in a new tab)

  4. Grant

    P30 · $326k · non-dilutive

    Sep 1, 2019

    BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI YANG, LIN · NIGMS · award ends Jun 30, 2029 · X-ray Scattering Technology Core

    NIH RePORTER · NIH RePORTER 11195021 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources